Fintel reports that on January 12, 2026, Barclays downgraded their outlook for Insulet (NasdaqGS:PODD) from Equal-Weight to ...

Insulet’s fair value estimate has been held steady at US$377.72 per share, with only fractional tweaks to the underlying ...

Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Fund” third-quarter 2025 investor ...

The Artisan Mid Cap Fund outpaced the Russell Midcap Growth Index in Q4 2025 despite a modest negative absolute return. Read ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...

With Q3 behind us, let’s have a look at ResMed (NYSE:RMD) and its peers. Patient monitoring companies within the healthcare ...

Detailed price information for C.H. Robinson Ww (CHRW-Q) from The Globe and Mail including charting and trades.

Insulet estimated that its total addressable market for automated insulin delivery will grow to a $9bn market value by 2028.

Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s price target on Insulet to $390 from $412 with a Buy rating on the shares.

Dr. Phil’s most famous interviewee is all grown up now, and has become one of the top earning creators on OnlyFans. Her celebrity appeal isn’t the only reason she’s one of the top earners on the ...